A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1024 participants.
Also called NCT06221969
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,024 participants
- Sponsor
- Registry
-
NCT06221969
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Canada, Colombia, India, South Africa, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT06221969. Randomized; no masking; primary purpose treatment. Start 2024-01-16 (actual); primary completion 2026-03-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Tirzepatide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06221969- Content hash
25738cea7a2c2d76c10bc4c66628e31424873e406c64243a63286e0c72d81ed5